{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-111613","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.984167+00:00","generated_at":"2026-06-03T08:52:14.242311+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"XOMA earns $9M milestone on FDA approval of Day One's OJEMDA for pediatric low-grade glioma","bullets":["XOMA earned $9M milestone from FDA accelerated approval of Day One's OJEMDA (tovorafenib) for relapsed/refractory BRAF-altered pLGG.","XOMA is entitled to a mid-single digit royalty on global OJEMDA sales; it is the first FDA-approved type II RAF inhibitor for this indication.","XOMA acquired rights in March 2021 from Viracta for $13.5M upfront, including $54M in potential milestones and royalties.","CEO Owen Hughes called the milestone a watershed event for children with BRAF-altered low-grade glioma."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-111613","json":"https://secwatch.observer/filing/0001193125-24-111613.json","markdown":"https://secwatch.observer/filing/0001193125-24-111613.md","text":"https://secwatch.observer/filing/0001193125-24-111613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524111613/0001193125-24-111613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524111613/d815676d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T08:52:14.242311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}